Polycystic ovary syndrome, recently reclassified in this work as polyendocrine metabolic ovarian syndrome (PMOS), is a common endocrine disorder affecting multiple systems including metabolism, reproduction, hormones and skin. Beyond the classical diagnostic features, pain — including dysmenorrhea, abdominal and pelvic pain — is frequently reported but has been comparatively underexplored. The study summarized here aimed to quantify pain prevalence among women with PMOS, to examine whether pain in PMOS is associated with increased risk of subsequent health conditions, to evaluate racial differences in prevalence and outcomes, and to assess whether commonly prescribed PMOS-related medications influence pain diagnoses.
This retrospective analysis used electronic health record (EHR) data from the TriNetX Global Network, comprising 120 health care organizations. The dataset included records for 103,675,738 women representing diverse racial backgrounds. The investigators identified women with PMOS and examined the prevalence of documented pain diagnoses within that group. The study calculated relative risk (RR) ratios for later health outcomes in women with PMOS overall and in the subgroup with both PMOS and pain, and stratified these analyses by self-reported race. Analyses were conducted in January 2026. The abstract reports broad methods and principal outcomes; detailed variable definitions, inclusion/exclusion criteria, covariate adjustments, and exact statistical procedures are not specified in the source excerpt.
Across the cohort of women with PMOS, 20.67% had pain documented in their EHR. Prevalence differed by self-reported race: the highest reported prevalence was among Black or African American women at 32.70%, followed by White women at 30.78%. The source emphasizes these racial differences as a key finding but does not provide additional stratified prevalence estimates for other racial groups within the abstract.
Women with PMOS were at increased relative risk for a range of future health conditions compared with reference comparators. The subgroup of women with both PMOS and pain exhibited even higher relative risks for several conditions. Specific conditions highlighted in the abstract and plain language summary include infertility, type 2 diabetes, liver disease, ovarian cysts, anxiety, depression, acute pharyngitis, and gastroesophageal reflux disease. The authors report that the degree of increased risk varied across racial groups, with statistically significant race-specific differences noted for outcomes such as infertility, ovarian cysts, obesity, and respiratory diseases. Exact relative risk values, confidence intervals, and p values are not reported in the abstract and therefore are not available in this source excerpt.
The authors report that women with PMOS who were prescribed PMOS-related medications experienced a decrease in pain diagnoses following treatment. The abstract and plain-language summary indicate an association between treatment and reduced documented pain but do not specify which medication classes or agents were analyzed, the duration of follow-up, or whether the analysis accounted for confounding by indication. Those methodological details were not reported in the excerpt provided.
The study’s principal implication is that pain should be more actively recognized and assessed as part of PMOS care. Given the finding that roughly one in five women with PMOS have documented pain and that pain identifies a subgroup with higher subsequent risks for multiple adverse health outcomes, routine pain assessment and targeted management may be important for improving long-term outcomes. The observed racial differences — notably higher pain prevalence among Black or African American women and differences in condition-specific risks across racial groups — suggest that clinicians and health systems should consider race-stratified patterns when developing care plans and that further work to address disparities is warranted.
The abstract provides robust population-level signals but leaves several methodological and interpretive questions unanswered in the source excerpt. The specific diagnostic criteria used to identify PMOS in the EHR, the precise codes used to define pain outcomes, the time windows for assessing subsequent conditions, and the statistical models and covariates used to calculate relative risks are not detailed. Information on which PMOS-related medications were evaluated, dosing, treatment adherence, and length of follow-up after treatment is also not reported here. As a result, causality cannot be inferred from the reported associations and more detailed reading of the full manuscript would be required to assess potential confounding, bias, and generalizability.
The abstract reports that Tess Cherlin was supported by NIH National Institute of General Medical Sciences (NIGMS) grant K12GM081259 (HHS). The conflict of interest statement in the source lists the authors and notes no competing interests declared.
In a large EHR-based cohort spanning 120 health care organizations and over 103 million women, 20.67% of women with PMOS had documented pain, with the highest prevalence among Black or African American and White women. Women with PMOS and pain exhibited higher relative risks for a range of future health conditions compared with PMOS overall, and documented pain diagnoses decreased after treatment with PMOS-related medications. The findings support routine pain screening and management within PMOS care pathways and indicate that racial differences should be considered when planning personalized interventions. The abstract omits several methodological details, medication specifics, and exact risk estimates, which are not available in the source excerpt.